Armata Pharmaceuticals, Inc.
ARMPAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 23, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 23, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2021 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2020 |
| H.C. Wainwright | maintain | Buy | May 15, 2020 |
| HC Wainwright & Co. | maintain | Buy | Mar 20, 2020 |
| H.C. Wainwright | maintain | Buy | Mar 20, 2020 |
| Maxim Group | maintain | Buy | Feb 6, 2020 |
| Ladenburg Thalmann | maintain | Buy | Jun 19, 2019 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.57| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.27 | $-0.45 | $2.5M | $400.0K |
| May 13, 2026 | $-3.16 | $-0.38 | $789.0K | $740.0K |
| Mar 25, 2026 | $-3.42 | $-0.19 | $1.1M | $740.0K |
| Nov 12, 2025 | $-0.74 | $-0.42 | $1.2M | $1.4M |
| Aug 12, 2025 | $-0.45 | $-0.39 | $2.2M | $1.4M |
| May 14, 2025 | $-0.20 | $-0.38 | $491.0K | $1.4M |
| Mar 20, 2025 | $-0.23 | $-0.35 | $1.2M | $1.6M |
| Nov 13, 2024 | $-0.15 | $-0.28 | $3.0M | $900.0K |
News
Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041 LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced issuance …
Armata Pharmaceuticals Inc. (AMEX:ARMP) shares are trading lower on Wednesday as traders digest additional non-dilutive funding tied to its lead bacteriophage program.
Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia New commitment is incremental to previously announced DoW funding and expands total non-dilutive support for the AP-SA02 program to $32.4 million LOS ANGELES, Sept. 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific…
Controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical drug product lots Oral presentation scheduled for today Monday, Sept. 21, 2026 at the 20 th International Symposium on Staphylococci and Staphylococcal Infections LOS ANGELES, Sept.
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies Potentially accelerating the path to market for this innovative antibacterial treatment AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, providing strong regulatory validation LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"…
LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D.
LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology, a peer-reviewed journal.
LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2026, and provided a corporate update. "We continue to finalize activities required to…